Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Do-Young | - |
dc.contributor.author | Song, Moo-Kon | - |
dc.contributor.author | Chung, Joo-Seop | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Yang, Deok Hwan | - |
dc.contributor.author | Lim, Sung-Nam | - |
dc.contributor.author | Oh, Sung-Yong | - |
dc.date.accessioned | 2022-07-08T20:27:33Z | - |
dc.date.available | 2022-07-08T20:27:33Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146665 | - |
dc.description.abstract | Background Systemic inflammatory response can be associated with the prognosis of diffuse large B cell lymphoma (DLBCL). We investigated the systemic factors significantly related to clinical outcome in relapsed/refractory DLBCL. Methods In 242 patients with DLBCL, several factors, including inflammatory markers were analyzed. We assessed for the correlation between the survivals [progression-free survival (PFS) and overall survival (OS)] and prognostic factors. Results In these patients, a high derived neutrophil/lymphocyte ratio (dNLR) (PFS, HR=2.452, P=0.002; OS, HR=2.542, P=0.005), high Glasgow Prognostic Score (GPS) (PFS, HR=2.435, P=0.002; OS, HR=2.621, P=0.002), and high NCCN-IPI (PFS, HR=2.836, P=0.003; OS, HR=2.928, P=0.003) were significantly associated with survival in multivariate analysis. Moreover, we proposed a risk stratification model based on dNLR, GPS, and NCCN-IPI, thereby distributing patients into 4 risk groups. There were significant differences in survival among the 4 risk groups (PFS, P<0.001; OS, P<0.001). Conclusion In conclusion, dNLR, GPS, and NCCN-IPI appear to be excellent prognostic parameters for survival in relapsed/refractory DLBCL. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC HEMATOLOGY | - |
dc.title | Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Moo-Kon | - |
dc.identifier.doi | 10.5045/br.2019.54.4.244 | - |
dc.identifier.scopusid | 2-s2.0-85079236980 | - |
dc.identifier.wosid | 000504060100004 | - |
dc.identifier.bibliographicCitation | BLOOD RESEARCH, v.54, no.4, pp.244 - 252 | - |
dc.relation.isPartOf | BLOOD RESEARCH | - |
dc.citation.title | BLOOD RESEARCH | - |
dc.citation.volume | 54 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 244 | - |
dc.citation.endPage | 252 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002532104 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | C-REACTIVE PROTEIN | - |
dc.subject.keywordPlus | PREDICTING SURVIVAL | - |
dc.subject.keywordPlus | PROGNOSTIC SCORE | - |
dc.subject.keywordPlus | NCCN-IPI | - |
dc.subject.keywordPlus | RATIO | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | NEUTROPHIL | - |
dc.subject.keywordAuthor | Derived neutrophil/lymphocyte ratio | - |
dc.subject.keywordAuthor | Glasgow prognostic score | - |
dc.subject.keywordAuthor | DLBCL | - |
dc.identifier.url | https://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2019.54.4.244 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.